Micropore Pathfinder for development of RNA/LNP therapeutics and vaccines

Click2Contact

Harnessing the capabilities of Micropore’s AXF mini, together with intuitive software, the AXF Pathfinder is a compact benchtop unit for discovery, development and phase 1 clinical development through to full GMP manufacture of nucleic acid therapeutics and vaccines.

The Pathfinder series is designed to turbocharge the next generation of RNA/LNP formulation development, allowing for seamless transitions to large-scale production. Micropore Technologies unveiled the Pathfinder 20, Pathfinder 50, Pathfinder 250 and Pathfinder 1000 at the 2nd Annual LNP Formulation & Process Development Summit, held in Boston from 17–19 April 2023. Using advanced cross flow technology, the series accelerates development by eliminating tech transfer iterations during scale-up, transitioning from DOE (design of experiments) screening to clinical production on a single device.

Discover mode enables initial formulation with minimised wastage for development and analysis. The AXF mini’s low internal volume means that start-up waste for the Pathfinder unit is only around 400 μL and sample sizes can be as small as 200 μL. High throughput screening of up to 96 samples can be achieved in less than a minute for rapid DOE and process optimisation. Importantly, researchers can enter at the Pathfinder 20 and upgrade to the Pathfinder 50, 250 or 1000 as their requirements dictate while maintaining the Discover mode functionality across all four systems.

Micropore technology is a transformative model designed to disrupt the current drug development paradigm by allowing rapid formulation screening and manufacturing without the need for a disposable cartridge.

For more information, visit https://www.atascientific.com.au/products/axf-pathfinder/ or contact ATA Scientific for a demonstration.